MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2026.03.040

Медицинская библиотека · Transplantation and cellular therapy · 2026

Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.

Reynolds Gemma K, Dowling Mark R, Valencia-Klug Jose, Teh Benjamin W, Anderson Mary Ann, Vanguru Vinay, Harrison Simon J, Ho P Joy, Slavin Monica A, Thursky Karin

СтатьяПеревод пока не подготовлен

Аннотация

Routine fluoroquinolone (FQ) prophylaxis may increase the risk of antimicrobial resistance, microbiome disruption, and Clostridioides difficile infection in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy for hematological malignancy. In Australia, FQ prophylaxis is not routinely used. We evaluated the etiology of early fever following CAR-T to better understand the incidence of infections, particularly bloodstream infections, in a cohort not receiving FQ prophylaxis. This bicentric Australian retrospective study included adults receiving standard-of-care CD19 CAR-T therapy for DLBCL (2019 to 2023). The primary outcome was the cause of sustained fever (≥38.0°C on ≥1 days) from infusion to day 30. Recurrent fever required ≥72 h afebrile before a new fever. Infections were classified as microbiologically confirmed, clinically defined, or fever syndrome per consensus criteria. About 204 adults (median age 64 years, IQR: 57 to 71) received tisagenlecleucel (50%) and axicabtagene (50%), after a median of 3 prior therapies (interquartile range [IQR]: 3 to 4). Sustained fever occurred in 131/204 patients (64%), comprising 161 episodes. Of these, 36 (21%, 28pts) were microbiologically confirmed infections, 14 (9%, 14pts) were clinically defined infections, and 110 (69%, 108pts) were fevers of unknown origin. Bacteremia occurred in 7/204 patients (3.4%; 9 events), with one fatal polymicrobial bacteremia. Other microbiologically confirmed infections included C. difficile (7/36), URTI (13/36) and invasive fungal infection (5/36). Risk factors for early microbiologically confirmed infection in univariate analysis included axicabtagene product (hazard ratio [HR] = 2.5, P = .019), grade ≥3 immune-cell associated neurotoxicity (HR = 3.4, P = .012), and prolonged neutropenia (absolute neutrophil count ≤ .5 × 10⁹/L for ≥14 days; HR = 3.7, P = .014). Early bacteremia rates remain low without routine FQ prophylaxis. Initial sustained fevers are predominantly noninfectious. Our data do not support universal FQ prophylaxis in CAR-T therapy.

Для цитирования: Reynolds Gemma K, Dowling Mark R, Valencia-Klug Jose, Teh Benjamin W, Anderson Mary Ann, Vanguru Vinay, Harrison Simon J, Ho P Joy, Slavin Monica A, Thursky Karin. Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.. Transplantation and cellular therapy. 2026. DOI: 10.1016/j.jtct.2026.03.040.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.